-
Research presented at the latest Clinical Meeting of the American College of Obstetricians and Gynecologists indicates that women using an oral contraceptive (OC) with a 26/2 dosing regimen had less severe hormone withdrawal-associated symptoms than those using a 21/7 pill.
-
-
Check your clinic storeroom for stock of the Sandoz oral contraceptive Introvale. The Princeton, NJ-based company issued a voluntary recall in June 2012 for 10 lots of the generic oral contraceptive following a recent report of a packaging flaw.
-
CME Objectives/CME Questions
-
Adults treated with glucocorticoids in a primary care setting have a five-fold increase in suicide or suicidal behavior and other severe neuropsychiatric disorders. The risk is highest with first-time use of these medications.
-
The presence of aortic valve calcification (AVC) predicts cardiovascular and coronary event risk independent of traditional risk factors and inflammatory biomarkers, likely due to the strong correlation between AVC and subclinical atherosclerosis.
-
Clinical Briefs: Risk for Zoster from the Vaccine in Immunosuppressed Persons, Elucidating the Best, Cerebral Aneurysms: Whats in Your
Patients Future?
-
Off-label prescribing is common in primary care and most of the time lacks the scientific evidence to support it.
-
The ECG was obtained from a patient whose blood pressure was dropping. How many reasons can you cite to support a diagnosis of ventricular tachycardia (VT)?
-
THE FDA HAS APPROVED A SECOND WEIGHT-LOSS DRUG WITHIN the last month. This product is a combination of phentermine, an anorectic, and the antiepileptic topiramate. Phentermine/topiramate (PHEN/TPM) is manufactured by Catalent Pharma Solutions and marketed by Vivus Inc. as Qsymia.
